323 related articles for article (PubMed ID: 11417472)
1. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
2. New nucleoside analogs in the treatment of solid tumors.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(4):297-305. PubMed ID: 15575597
[TBL] [Abstract][Full Text] [Related]
3. [Clinical pharmacology of nucleoside analogues].
Milano G; Chamorey AL; Thyss A
Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
5. [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Jordheim LP; Galmarini CM; Dumontet C
Bull Cancer; 2005 Mar; 92(3):239-48. PubMed ID: 15820918
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
7. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside analogues in the treatment of haematological malignancies.
Johnson SA
Expert Opin Pharmacother; 2001 Jun; 2(6):929-43. PubMed ID: 11585009
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
13. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
Schirmer M; Stegmann AP; Geisen F; Konwalinka G
Exp Hematol; 1998 Dec; 26(13):1223-8. PubMed ID: 9845378
[TBL] [Abstract][Full Text] [Related]
14. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological basis for cladribine resistance.
Lotfi K; Juliusson G; Albertioni F
Leuk Lymphoma; 2003 Oct; 44(10):1705-12. PubMed ID: 14692522
[TBL] [Abstract][Full Text] [Related]
16. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
17. New purine analogues for the treatment of chronic B-cell malignancies.
Gribbin TE
Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
[TBL] [Abstract][Full Text] [Related]
18. Seeking the nucleoside transporter.
Wiley JS
Nat Med; 1997 Jan; 3(1):25-6. PubMed ID: 8986733
[No Abstract] [Full Text] [Related]
19. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
20. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
